Latest Breaking News On - R nolan townsend - Page 1 : comparemela.com

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression data.

Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 8:15 AM PT in San Francisco, California. The event will be we

Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

18.12.2023 - NEW YORK, Dec. 18, 2023 (GLOBE NEWSWIRE) - Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer s . Seite 1

Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights

Completed enrollment of the LEAD Phase 1/2 clinical trial of LX1001 for the treatment of APOE4-associated Alzheimer’s disease

Sarepta Makes Strategic Investment in Lexeo to Support Development of Cardiovascular Gene Therapies